The current generation of CAR-T approaches for hematological malignancies generate strong responses in cancer patients, but too often progression-free survival is less than 12 months. The next-generation allogeneic approaches may make these therapies more accessible to the patients who need them but have been hampered by poor in vivo persistence.
22-23 August 2022